Abstract

Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
Hervé Tilly ...
Blood | VOL. 138
Hervé Tilly, et. al.Hervé Tilly ...
04 Dec 2021
Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy
Tycel Phillips ... Carmelo Carlo-Stella
Blood | VOL. 138
Tycel Phillips, et. al.Tycel Phillips ... Carmelo Carlo-Stella
05 Nov 2021
Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study
...
Blood | VOL. 138
, et. al. ...
05 Nov 2021
Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts)
Michael Dickinson ... Martin Hutchings
Blood | VOL. 138
Michael Dickinson, et. al.Michael Dickinson ... Martin Hutchings
05 Nov 2021
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Herpetic lymphadenitis mimicking Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma
Samuel Bidot ... Andrew L Feldman
Blood | VOL. 143
Samuel Bidot, et. al.Samuel Bidot ... Andrew L Feldman
27 Jun 2024
GM-CSF brings (good) memories
Damien Reynaud
Blood | VOL. 143
Damien ReynaudDamien Reynaud
27 Jun 2024
Introduction to a review series on oncogenic signaling and immune evasion in hematologic malignancies
Robert Zeiser
Blood | VOL. 143
Robert ZeiserRobert Zeiser
27 Jun 2024
Crespiatico I, Zaghi M, Mastini C, et al. First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis. Blood. 2024;143(14):1399-1413.
-
Blood | VOL. 143
--
27 Jun 2024
View more papers